Analysis of the Detection Rate and Results of Surgical Treatment of Patients with Infective Endocarditis With/Without COVID-19

   AIM OF STUDY. To analyze results of surgical treatment of infective endocarditis in the context of the COVID-19 pandemic at the N. V. Sklifosovsky Research Institute for Emergency Medicine.

   MATERIAL AND METHODS. From January, 2021 to April, 2022 at N.V. Sklifosovsky Research Institute for Emergency Medicine we performed 59 surgical interventions on patients diagnosed with infective endocarditis, of which 20 patients (33.9%) had a competing diagnosis “new coronavirus infection”.

   RESULTS. The overall mortality was for the specified period was 18.6 %, 11 patients. In the first group, 5 patients died (25 %). Hospital mortality in the second group was 6 patients (15.4 %).

   CONCLUSION. Preoperative preparation, as well as the surgical intervention itself, did not differ significantly between patients in the two groups. Hospital mortality in the group of patients with new coronavirus infection was higher than in patients without the virus, despite the fact that the risk of surgical intervention according to EuroSCORE II was higher in the second group. From which we can conclude that the EuroSCORE risk scale II does not fully reflect the initial severity of the condition of patients with COVID-19. Such risk factors as decreased immunity due to immunosuppressive therapy and respiratory failure and coagulopathy influenced the results of surgical treatment of infective endocarditis in this cohort of patients, but not so significantly as to refuse surgical intervention. The significant difference in the postoperative period was the increase in bed days in intensive care and therapeutic departments among patients with COVID-19. This factor is associated with the initial severity and specifics of management of these patients in the postoperative period, which required greater vigilance and attention from cardiac surgeons, resuscitators and infectious disease doctors in the “red” zones.

1. Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020;21:100331. PMID: 32292899 doi: 10.1016/j.eclinm.2020.100331

2. Kumanayaka D, Mutyala M, Reddy DV, Slim J. Coronavirus Disease 2019 Infection as a Risk Factor for Infective Endocarditis. Cureus. 2021;13(5): e14813. PMID: 34094767 doi: 10.7759/cureus.14813

3. Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020;141(23):1930–1936. PMID: 32243205 doi: 10.1161/CIRCULATIONAHA.120.047164

4. Kotova EO, Pisaryuk AS, Kobalava ZhD, Timofeeva YuA, Chipigina NS, Karaulova YuN, et al. Infective endocarditis and COVID-19: the impact of SARS-CoV-2 infection on diagnostics, course, and prognosis. Russian Journal of Cardiology. 2023;28(1):5229. (In Russ.) doi: 10.15829/1560-4071-2023-5229

5. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for CardioThoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075–3128. PMID: 26320109 doi: 10.1093/eurheartj/ehv319

6. Habib G, Erba PA, Iung B, Donal E, Cosyns B, Larocheet C, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J. 2019;40(39):3222–3232. PMID: 31682254 doi: 10.1093/eurheartj/ehz803

7. Demin AA, Kobalava JD, Skopin II, Tyurin VP, Boytsov SA, Golukhova EZ, et al. Infectious endocarditis and infection of intracardiac devices in adults. Clinical guidelines 2021. Russian Journal of Cardiology. 2022;27(10):113–192. (In Russ.) doi: 10.15829/1560-4071-2022-5233

8. Kotova EO, Moiseeva AYu, Kobalava ZhD, Domonova EA, Pisaruk AS, Silveistrova OYu, et al. Effect of Antibiotic Therapy on the Sensitivity of Etiological Diagnostic Methods in Patients with Infective Endocarditis after Surgery. Rational Pharmacotherapy in Cardiology. 2023;19(1):34–42. (In Russ.) doi: 10.20996/1819-6446-2023-02-03

9. Korber F, Zeller I, Grünstäudl M, Willinger B, Apfalter P, Hirschl AM, et al. SeptiFast versus blood culture in clinical routine – A report on 3 years experience. Wien Klin Wochenschr. 2017;129(11–12):427–434. PMID: 28243751 URL: https://www.researchgate.net/publication/314092906_SeptiFast_versus_blood_culture_in_clinical_routine_-_A_report_on_3_years_experience

10. Linschoten M, Peters S, van Smeden M, Jewbali LS, Schaap J, Siebelink H- M, et al. Cardiac complications in patients hospitalised with COVID-19. Eur Heart J Acute Cardiovasc Care. 2020;9(8):817–823. PMID: 33222494 doi: 10.1177/2048872620974605

11. Zhuravel SV, Ivanov IV, Talyzin AM, Klychnikova EV, Bulanov AYu, Popugaev KA, et al. Specific Changes in Hemostasis System Parameters during Extracorporeal Membrane Oxygenation in Patients with a Novel Coronavirus Infection. Messenger of Anesthesiology and Resuscitation. 2022;19(4):15–21. (In Russ.) doi: 10.21292/2078-5658-2022-19-4-15-21

12. Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020;141(23):1930–1936. URL: https://www.researchgate.net/publication/340424998_The_Variety_of_Cardiovascular_Presentations_of_COVID-19

13. Zhuravel SV, Vladimirov VV, Gavrilov PV, Ivanov IV, Petrikov SS, Popugayev KA, et al. Antithrombin-III for New Coronavirus Infection (COVID-19) Under Conditions of Extracorporeal Membrane Oxygenation (Clinical Observation). Russian Sklifosovsky Journal Emergency Medical Care. 2021;10(4):642–648. doi: 10.23934/2223-9022-2021-10-4-642-648

14. Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (2019-nCoV). Versiya 1.29.01.2020. (in Russ.) Available at: https://www.garant.ru/products/ipo/prime/doc/73380395/ [Accessed Jun 07, 2023]

15. XinPei Liu, Qi Miao, XingRong Liu, GuoTao Ma, JianZhou Liu. Outcomes of surgical treatment for active infective endocarditis under COVID-19 pandemic. J Card Surg. 2022;37:1161–1167. doi: 10.1111/jocs.16280

16. Pommier T, Benzenine E, Bernard C, Mariet A-S, Béjot Y, Giroud M, et al. Trends of Myocarditis and Endocarditis Cases before, during, and after the First Complete COVID-19-Related Lockdown in 2020 in France. Biomedicines. 2022;10(6):1231. PMID: 35740252 doi: 10.3390/biomedicines10061231

17. Quintero-Martinez J-R, Hindy JR, Mahmood M, Gerberi DJ, DeSimone DC, Baddour LM. A clinical profile of infective endocarditis in patients with recent COVID-19 : A systematic review. Am J Med Sci. 2022;364(1):16–22. PMID: 35235813 doi: 10.1016/j.amjms.2022.02.005

18. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020;396(10243):27–38. PMID: 32479829 doi: 10.1016/S0140-6736(20)31182-X Erratum in: Lancet. 2020; 396(10246):238. doi: 10.1016/S0140-6736(20)31350-7

19. Kokov LS, Petrikov SS, Pisankina MM, Dashevsky EA, Popugayev KA, Parkhomenko MV, et al. Course and Outcomes of Acute Coronary Syndrome in the Presence of New Coronavirus Infection COVID-19. Russian Sklifosovsky Journal Emergency Medical Care. 2022;11(2):238–248. doi: 10.23934/2223-9022-2022-11-2-238-248

20. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45(8):100618. PMID: 32439197 doi: 10.1016/j.cpcardiol.2020.100618